One year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study.

The results support the use of mepolizumab as an effective option in the current standard of care for patients affected by severe, uncontrolled CRSwNP especially in decreasing nasal polyps’ size and improving quality of life, although a minor impact was observed on recovery of smell.